华法令和肠溶阿司匹林防治高龄不稳定型心绞痛的疗效对比

Comparison between warfarin and aspirin on treatment of unstable angina pectoris in elder patients

目的探讨华法令和肠溶阿司匹林用于预防不稳定型心绞痛患者发生急性心肌梗死和心脏性死亡的疗效。方法应用统一人群分组对照群组研究的方法,在本院住院和门诊的高龄患者中随机挑选服用阿司匹林(ASA300mg/d)者73例,服用华法令(WFR2～5mg/d)者82例,并随访12个月。结果用药14d后,WFR组患者心绞痛改善率明显高于ASA组(86.6%vs67.1%),P<0.01。随访12个月期间,复合终点事件(非致死性急性心肌梗死和心脏性死亡)WFR组明显低于ASA组(9.8%vs26.0%),P<0.01。结论华法令防治不稳定型心绞痛的近期和远期疗效显著,优于阿司匹林组,小剂量应用副作用小,值得推广。

Objective To explore the effect of warfarin and aspirin on the prevention of acute myocardial infarction and sudden cardiac death in patients with unstable angina pectoris. Methods Studying on the contrast groups which are divided from the unitary crowd, among the aged cases from our hospital, we randomly sampled 73 cases to take aspirin 300 mg/d, and 82 to take warfarin 2-5 mg/d. Then we followed them up for 12 months. Results Fourteen days after the patients＇ medicine-taking, the rate of improvement in warfarin group was obviously higher than that of the aspirin group （86.6% vs 67.1%, P〈0.01）. During the 12-month follow up, the composite end point （unfatal acute myocardial infarction and cardiac death） of the warfarin group was obviously lower than that of the aspirin group（9.8% vs 26.0%, P〈0.01）. Conclusion Warfarin has outstanding effect on the treatment of unstable angina pectoris both in the near and specified future, and its side effect is mild when used in low dosage.